Latest Articles

EAS guidance regarding combining Lipid-modifying therapy

Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients

Act Now for Your ACS Patients: Optimize Your ACS Pathway

Cardiovascular diseases (CVDs) are the leading cause of death globally¹

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹. A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Approach for Patients with CAD: Focus on LDL-C Control

Lipid Management in Patients with Diabetes Mellitus

Approach for Patients with PAD and T2D: Focus on LDL-C Control

ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci